Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer

Dr. Melnick to lead clinical team as Spero prepares to enter late-stage clinical trials CAMBRIDGE, Mass. , Jan. 04, 2018 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel

READ FULL TEXT

Leave a Reply

Your email address will not be published.